In a new clinical trial, UC Davis Health will test the efficacy and safety of REGN-COV2 (a monoclonal antibody mixture) in the prevention of COVID-19 in adults with the infection. The drug was recently administered to President Donald Trump as part of a treatment for SAR-CoV-2 infection. It is still in clinical trials as a potential treatment and prevention for COVID-19.
Stuart Cohen, chief of infectious diseases at UC Davis Health and the hospital's director of epidemiology and infection prevention, will oversee the clinical trial and help recruit participants.
Cohen said, "We at UC Davis Health are excited to participate in this clinical trial and to study antibodies that have been used in the past to prevent many viral infections, such as hepatitis B." "We will be testing the ability of REGN-COV2 to prevent COVID-19 infection in people who are already in close contact with confirmed patients, such as family members,"
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Specialty chemicals industry expected to return to growth in 2021
Sugar-free brings a new wave of growth opportunities for beverage industry
Dyestuffs gain momentum on shrinking demand for raw materials
Ethanol Production Rises, U.S. Corn Back on the Rise
Overview of chemical pesticide raw material production in five provinces
Market uncertainty increases, oil Q4 trend is still biased strong